Foghorn Therapeutics Inc. (FHTX) Misses Q2 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Foghorn Therapeutics Inc. (FHTX) Misses Q2 EPS by 9c

Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update

August 9, 2022 7:01 AM EDT

- FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues to progress per protocol; working to resolve partial clinical hold in AML and MDS

- On track to report initial Phase 1 clinical data for FHD-609 in synovial sarcoma in 2023

- Research milestone achieved under Merck collaboration in July, triggering $5 million milestone payment to Foghorn in the third quarter 2022

- Cash, cash equivalents and marketable securities of $394.7 million, as of June 30, 2022, provides significant cash runway

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Foghorn®... More